BC
BRNS

Brookfield Corp’s Barinthus Biotherapeutics BRNS Stock Holding History

Brookfield Corp’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,921
Closed -$251K – 640
2021
Q3 		$251K Sell
15,921
-9,079
-36% -$138K ﹤0.01% 490
2021
Q2 		$420K Buy
+25,000
New +$370K ﹤0.01% 509

Other funds holding BRNS

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
MGIM
M&G Investment Management London, United Kingdom $28.2B AUM 25.87% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.5B AUM 13.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IIM
Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

Brookfield Corp's BRNS Position: Q4 2021 in Review

Brookfield Corp sold out of Barinthus Biotherapeutics (BRNS) in Q4 2021, closing a stake of 15,921 shares — an estimated $251K sold.

Brookfield Corp first reported a position in BRNS in Q2 2021 and held it in 2 quarters. The position peaked at $420K in Q2 2021. 15 funds tracked by Wall St. Rank hold BRNS as of Q4 2021.

  • Brookfield Corp reported no remaining Barinthus Biotherapeutics position as of Q4 2021 after selling out during the quarter.
  • Brookfield Corp sold 15,921 Barinthus Biotherapeutics shares in Q4 2021, an estimated $251K.
  • Brookfield Corp first reported a position in Barinthus Biotherapeutics in Q2 2021 and held it in 2 quarters.
  • Brookfield Corp's Barinthus Biotherapeutics position peaked at $420K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q4 2021.

Based on Brookfield Corp's 13F filing for Q4 2021, filed 14 Feb 2022.